Skip to content

Inspection Record

Noble Life Sciences, Inc — FDA 483 Findings

US FDAInspected 2025-06-20Published 2026-10-26 3 findingsDeviation, CAPA, and investigationEquipment and facility

Inspectors Hugh M Mcclure · Christine M Smith · Amanda M SzucsikThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

The quality assurance unit failed to determine whether any deviations from approved protocols or standard operating procedures had been made without proper authorization and documentation.

2Equipment and facility

Not all animal cages, racks and accessory equipment were cleaned and sanitized at appropriate intervals.

3Equipment and facility

Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Noble Life Sciences, Inc company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.